Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery
- 29 October 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 24 (23) , 13614-13620
Abstract
Diabetes is a set of diseases characterized by defects in insulin utilization, either through autoimmune destruction of insulin-producing cells (Type I) or insulin resistance (Type II). Treatment options can include regular injections of insulin, which can be painful and inconvenient, often leading to low patient compliance. To overcome this problem, novel formulations of insulin are being investigated, such as inhaled aerosols. Sufficient deposition of powder in the peripheral lung to maximize systemic absorption requires precise control over particle size and density, with particles between 1 and 5 μm in aerodynamic diameter being within the respirable range. Insulin nanoparticles were produced by titrating insulin dissolved at low pH up to the pI of the native protein, and were then further processed into microparticles using solvent displacement. Particle size, crystallinity, dissolution properties, structural stability, and bulk powder density were characterized. We have demonstrated that pure drug insulin microparticles can be produced from nanosuspensions with minimal processing steps without excipients, and with suitable properties for deposition in the peripheral lung.Keywords
This publication has 29 references indexed in Scilit:
- Biodegradable Nanoparticle Flocculates for Dry Powder Aerosol FormulationLangmuir, 2007
- Amorphous Drug Nanosuspensions. 3. Particle Dissolution and Crystal GrowthLangmuir, 2007
- NanoCipro encapsulation in monodisperse large porous PLGA microparticlesJournal of Controlled Release, 2007
- Developing a Pulmonary Insulin Delivery System for Patients with DiabetesClinical Therapeutics, 2007
- Amorphous Drug Nanosuspensions. 1. Inhibition of Ostwald RipeningLangmuir, 2005
- Pulmonary Interleukin-23 Gene Delivery Increases Local T-Cell Immunity and Controls Growth ofMycobacterium tuberculosisin the LungsInfection and Immunity, 2005
- Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles1Diabetic Medicine, 2004
- Factors Affecting the Deposition of Inhaled Porous Drug ParticlesJournal of Pharmaceutical Sciences, 2002
- Histopathological study of the effects of a single intratracheal instillation of surface activeagents on lung in rats.The Journal of Toxicological Sciences, 2000
- Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matricesJournal of Pharmaceutical Sciences, 1963